(3-苯基-丙基氨基)-乙醛二甲基缩醛 | 775343-47-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (3-苯基-丙基氨基)-乙醛二甲基缩醛
• 英文名称: (3-phenyl-propylamino)-acetaldehyde dimethylacetal
• 英文别名: (2,2-Dimethoxy-aethyl)-(3-phenyl-propyl)-amin；N-(2,2-dimethoxyethyl)-3-phenylpropan-1-amine
• CAS: 775343-47-0
• 化学式: C₁₃H₂₁NO₂
• mdl: MFCD12148452
• 分子量: 223.315
• InChiKey: XFQIKUPHOZXKHJ-UHFFFAOYSA-N

物化性质

• 沸点：
  306.1±32.0 °C(Predicted)
• 密度：
  0.985±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3-苯基-丙基氨基)-乙醛二甲基缩醛 在 哌啶 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 反应 4.5h， 生成
  参考文献：
  名称：

  作为凋亡蛋白 (IAP) 抑制剂拮抗剂的咪唑并吡嗪酮衍生物的设计、合成和生物学评价

  摘要：

  凋亡抑制剂 (IAP) 蛋白在许多癌症中过度表达并与肿瘤生长有关，因此开发可破坏 IAP 与其伙伴蛋白结合的拮抗剂是一种很有前景的治疗策略。为了增加细胞活性并改善有利的类药物特性，我们新设计并合成了基于9咪唑并吡嗪酮结构的单价类似物。细胞效力的优化导致17的鉴定，这表 明亚微摩尔活性 (GI 50 = 234 nM) 和 Caspase-3 激活（6.3 倍）在 MDA-MB-231 乳腺癌细胞中增加。这些发现清楚地表明了17 作为开发有效抗癌治疗的有前途的单价拮抗剂。

  DOI：

  10.1002/bkcs.12271
• 作为产物：
  描述：

  3-苯丙酰氯 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 3.5h， 生成 (3-苯基-丙基氨基)-乙醛二甲基缩醛
  参考文献：
  名称：

  Multisubstrate inhibitors of dopamine .beta.-hydroxylase. 1. Some 1-phenyl and 1-phenyl-bridged derivatives of imidazole-2-thione

  摘要：

  The synthesis and characterization of some 1-(phenylalkyl)imidazole-2-thiones as a novel class of "multisubstrate" inhibitors of dopamine beta-hydroxylase (DBH) are described. These inhibitors incorporate structural features that resemble both tyramine and oxygen substrates, and as evidenced by steady-state kinetics, they appear to bind both the phenethylamine binding site and the active site copper atom(s) in DBH. A series of structural congeners that incorporate different bridging chain lengths between the phenyl ring (dopamine mimic) and the imidazole-2-thione group (oxygen mimic) define the optimum distance for inhibitory potency and the likely intersite distance in the DBH active site. Additional bridging analogues were prepared to determine the active site bulk tolerance and the effects of heteroatom replacement.

  DOI：

  10.1021/jm00162a008

文献信息

• Benzohydryl Ethers of 2-Benzylaminoethanol and 2-(2-Pyridyl)-aminoethanol
  作者：Irving Allan Kaye

  DOI：10.1021/ja01155a534

  日期：1951.11
• Design, Synthesis, and Biological Evaluation of Imidazopyrazinone Derivatives as Antagonists of <scp>Inhibitor of Apoptosis Proteins</scp> (IAPs)
  作者：Jisook Kim、Inhwan Bae、Jiyoung Song、Younghoon Kim、Younggil Ahn、Hyun‐Ju Park、Ha Hyung Kim、Dae Kyong Kim

  DOI：10.1002/bkcs.12271

  日期：2021.6

  proteins are overexpressed in many cancers and implicated in tumor growth, so the development of antagonist that disrupts with the binding of IAP to their partner protein is a promising therapeutic strategy. In an effort to increase cellular activity and improve favorable drug-like properties, we newly designed and synthesized monovalent analogues based on imidazopyrazinone structure of 9. Optimization

  凋亡抑制剂 (IAP) 蛋白在许多癌症中过度表达并与肿瘤生长有关，因此开发可破坏 IAP 与其伙伴蛋白结合的拮抗剂是一种很有前景的治疗策略。为了增加细胞活性并改善有利的类药物特性，我们新设计并合成了基于9咪唑并吡嗪酮结构的单价类似物。细胞效力的优化导致17的鉴定，这表 明亚微摩尔活性 (GI 50 = 234 nM) 和 Caspase-3 激活（6.3 倍）在 MDA-MB-231 乳腺癌细胞中增加。这些发现清楚地表明了17 作为开发有效抗癌治疗的有前途的单价拮抗剂。
• Multisubstrate inhibitors of dopamine .beta.-hydroxylase. 1. Some 1-phenyl and 1-phenyl-bridged derivatives of imidazole-2-thione
  作者：Lawrence I. Kruse、Carl Kaiser、Walter E. DeWolf、James S. Frazee、Eleanor Garvey、Eileen L. Hilbert、Wayne A. Faulkner、Kathryn E. Flaim、John L. Sawyer、Barry A. Berkowitz

  DOI：10.1021/jm00162a008

  日期：1986.12

  The synthesis and characterization of some 1-(phenylalkyl)imidazole-2-thiones as a novel class of "multisubstrate" inhibitors of dopamine beta-hydroxylase (DBH) are described. These inhibitors incorporate structural features that resemble both tyramine and oxygen substrates, and as evidenced by steady-state kinetics, they appear to bind both the phenethylamine binding site and the active site copper atom(s) in DBH. A series of structural congeners that incorporate different bridging chain lengths between the phenyl ring (dopamine mimic) and the imidazole-2-thione group (oxygen mimic) define the optimum distance for inhibitory potency and the likely intersite distance in the DBH active site. Additional bridging analogues were prepared to determine the active site bulk tolerance and the effects of heteroatom replacement.